US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
FR2640638B1
(fr)
|
1988-12-20 |
1991-02-15 |
Commissariat Energie Atomique |
Bioreacteur et dispositif pour la culture de cellules animales
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
US5387484A
(en)
|
1992-07-07 |
1995-02-07 |
International Business Machines Corporation |
Two-sided mask for patterning of materials with electromagnetic radiation
|
CA2592997A1
(en)
|
1992-12-03 |
1994-06-09 |
Genzyme Corporation |
Pseudo-adenovirus vectors
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
DK0667912T3
(da)
|
1993-07-13 |
2008-11-10 |
Centelion |
Defekte adenovirusvektorer og anvendelse heraf i genterapi
|
EP0755454B1
(en)
|
1994-04-13 |
2008-02-13 |
The Rockefeller University |
Aav-mediated delivery of dna to cells of the nervous system
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
WO1996017947A1
(en)
|
1994-12-06 |
1996-06-13 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant aav vectors
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5756283A
(en)
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US5688676A
(en)
|
1995-06-07 |
1997-11-18 |
Research Foundation Of State University Of New York |
In vitro packaging of adeno-associated virus DNA
|
US5741683A
(en)
|
1995-06-07 |
1998-04-21 |
The Research Foundation Of State University Of New York |
In vitro packaging of adeno-associated virus DNA
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
US6197293B1
(en)
|
1997-03-03 |
2001-03-06 |
Calydon, Inc. |
Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
|
US6143548A
(en)
|
1995-08-30 |
2000-11-07 |
Genzyme Corporation |
Chromatographic purification of adeno-associated virus (AAV)
|
US7026468B2
(en)
|
1996-07-19 |
2006-04-11 |
Valentis, Inc. |
Process and equipment for plasmid purification
|
WO1998010088A1
(en)
|
1996-09-06 |
1998-03-12 |
Trustees Of The University Of Pennsylvania |
An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
|
ATE550429T1
(de)
|
1996-11-20 |
2012-04-15 |
Crucell Holland Bv |
Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
EP0950091A2
(en)
|
1996-12-18 |
1999-10-20 |
Targeted Genetics Corporation |
Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
|
US6156303A
(en)
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
US6989264B2
(en)
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
EP1015619A1
(en)
|
1997-09-19 |
2000-07-05 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
WO1999014354A1
(en)
|
1997-09-19 |
1999-03-25 |
The Trustees Of The University Of The Pennsylvania |
Methods and vector constructs useful for production of recombinant aav
|
US6410300B1
(en)
|
1998-01-12 |
2002-06-25 |
The University Of North Carolina At Chapel Hill |
Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
JP2002506652A
(ja)
|
1998-03-20 |
2002-03-05 |
トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパーを含まない製造のための組成物及び方法
|
FR2778413B1
(fr)
|
1998-05-07 |
2000-08-04 |
Immunotech Sa |
Nouveaux reactifs et methode de lyse des erythrocytes
|
EP1080218A1
(en)
|
1998-05-27 |
2001-03-07 |
University of Florida |
Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
|
GB2338236B
(en)
|
1998-06-13 |
2003-04-09 |
Aea Technology Plc |
Microbiological cell processing
|
US6900049B2
(en)
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
MXPA01004169A
(es)
|
1998-10-27 |
2002-06-04 |
Crucell Holland Bv |
Produccion mejorada de vector de virus adenoasociados.
|
WO2000028004A1
(en)
|
1998-11-10 |
2000-05-18 |
The University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
US6689600B1
(en)
|
1998-11-16 |
2004-02-10 |
Introgen Therapeutics, Inc. |
Formulation of adenovirus for gene therapy
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
US6258595B1
(en)
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
AU2409200A
(en)
|
1999-06-02 |
2000-12-28 |
Trustees Of The University Of Pennsylvania, The |
Compositions and methods useful for production of recombinant viruses which require helper viruses
|
US6399385B1
(en)
|
1999-09-29 |
2002-06-04 |
The Trustees Of The University Of Pennsylvania |
Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
US6334998B1
(en)
|
1999-12-07 |
2002-01-01 |
Parker Hughes Institute |
Estrogens for treating ALS
|
US7048920B2
(en)
|
2000-03-24 |
2006-05-23 |
Cell Genesys, Inc. |
Recombinant oncolytic adenovirus for human melanoma
|
EP1302542B1
(en)
|
2000-07-18 |
2007-06-13 |
Takeda Pharmaceutical Company Limited |
Novel physiologically active peptide and use thereof
|
US6593123B1
(en)
|
2000-08-07 |
2003-07-15 |
Avigen, Inc. |
Large-scale recombinant adeno-associated virus (rAAV) production and purification
|
FR2813891B1
(fr)
|
2000-09-14 |
2005-01-14 |
Immunotech Sa |
Reactif multifonctionnel pour erythrocytes mettant en jeu des carbamates et applications
|
ATE303808T1
(de)
|
2000-10-24 |
2005-09-15 |
Mitsubishi Pharma Corp |
Mittel zur behandlung der amyotrophischen lateralsklerose (als)
|
EP2017338A1
(en)
|
2001-05-24 |
2009-01-21 |
Genzyme Corporation |
Muscle-specific expression vectors
|
EP2270024B1
(en)
|
2001-06-21 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
NZ600121A
(en)
|
2001-11-13 |
2013-12-20 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
CA2469623C
(en)
|
2001-12-12 |
2012-05-29 |
F H Faulding & Co Limited |
Composition for the preservation of viruses
|
CN1617938A
(zh)
|
2002-01-16 |
2005-05-18 |
戴诺生物技术有限公司 |
从单个样品中分离核酸和蛋白质的方法
|
MXPA04010603A
(es)
|
2002-04-30 |
2004-12-13 |
Oncolytics Biotech Inc |
Metodos mejorados de purificacion viral.
|
US20050196854A1
(en)
|
2002-05-14 |
2005-09-08 |
Konz John O.Jr. |
Methods of adenovirus purification
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
WO2003104413A2
(en)
|
2002-06-05 |
2003-12-18 |
University Of Florida |
Production of pseudotyped recombinant aav virions
|
US20050196862A1
(en)
*
|
2002-08-30 |
2005-09-08 |
Wooddell Christine I. |
DNA cassette for cellular expression of small RNA
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
CA2505514A1
(en)
|
2002-11-06 |
2004-05-27 |
Mount Sinai School Of Medicine |
Treatment of amyotrophic lateral sclerosis with nimesulide
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
CA2509494A1
(en)
|
2002-12-11 |
2004-06-24 |
University Of Massachusetts |
Method of introducing sirna into adipocytes
|
ES2521682T3
(es)
|
2003-05-21 |
2014-11-13 |
Genzyme Corporation |
Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
|
PL1633772T3
(pl)
|
2003-06-19 |
2016-10-31 |
|
Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
|
US7291498B2
(en)
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
US7491508B2
(en)
|
2003-06-20 |
2009-02-17 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
WO2005007676A2
(en)
|
2003-07-10 |
2005-01-27 |
Rajadhyaksha V J |
Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
|
WO2005072364A2
(en)
|
2004-01-27 |
2005-08-11 |
University Of Florida |
A modified baculovirus expression system for production of pseudotyped raav vector
|
PT1714960T
(pt)
|
2004-02-09 |
2018-05-02 |
Mitsubishi Tanabe Pharma Corp |
Um agente terapêutico inovador para a esclerose lateral amiotrófica (ela) ou doenças provocadas pela ela
|
WO2005096781A2
(en)
|
2004-04-06 |
2005-10-20 |
University Of Massachusetts |
Methods and compositions for treating gain-of-function disorders using rna interference
|
ES2647477T3
(es)
|
2004-06-01 |
2017-12-21 |
Genzyme Corporation |
Composiciones y métodos para prevenir la agregación del vector AAV
|
US7901921B2
(en)
|
2004-10-22 |
2011-03-08 |
Oncolytics Biotech Inc. |
Viral purification methods
|
WO2006066203A2
(en)
|
2004-12-16 |
2006-06-22 |
Alsgen, Llc |
Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod)
|
US8614101B2
(en)
|
2008-05-20 |
2013-12-24 |
Rapid Pathogen Screening, Inc. |
In situ lysis of cells in lateral flow immunoassays
|
US7625570B1
(en)
|
2005-03-10 |
2009-12-01 |
The Regents Of The University Of California |
Methods for purifying adeno-associated virus
|
WO2006119432A2
(en)
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
EP1986609A2
(en)
|
2006-01-26 |
2008-11-05 |
University of Massachusetts |
Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
|
WO2007098607A1
(en)
|
2006-03-03 |
2007-09-07 |
Amorfix Life Sciences Ltd. |
Methods and compositions to treat and detect misfolded-sod1 mediated diseases
|
ES2400235T3
(es)
|
2006-04-28 |
2013-04-08 |
The Trustees Of The University Of Pennsylvania |
Método de producción escalable de AAV
|
AU2007257093A1
(en)
|
2006-05-05 |
2007-12-13 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
US8183219B2
(en)
|
2007-01-03 |
2012-05-22 |
Medtronic, Inc. |
Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
|
EP2680007A1
(en)
|
2007-02-08 |
2014-01-01 |
Biogen Idec MA Inc. |
Nrf2 screening assays and related methods and compositions
|
US20090036395A1
(en)
|
2007-04-26 |
2009-02-05 |
Davidson Beverly L |
Rna interference suppression of neurodegenerative diseases and methods of use thereof
|
EP2019143A1
(en)
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
WO2009014445A2
(en)
|
2007-07-26 |
2009-01-29 |
Amsterdam Molecular Therapeutics B.V. |
Baculoviral vectors comprising repeated coding sequences with differential codon biases
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
CA2713338C
(en)
|
2008-01-29 |
2021-10-26 |
Applied Genetic Technologies Corporation |
Recombinant virus production using mammalian cells in suspension
|
JP5328244B2
(ja)
|
2008-07-07 |
2013-10-30 |
株式会社ニュージェン・ファーマ |
筋萎縮性側索硬化症治療剤
|
US8664189B2
(en)
|
2008-09-22 |
2014-03-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in skin indications
|
CA2744016C
(en)
|
2008-11-20 |
2018-12-11 |
Cambria Pharmaceuticals, Inc. |
Treatment of amyotrophic lateral sclerosis
|
EP2435575A2
(en)
|
2009-05-28 |
2012-04-04 |
Deutsches Krebsforschungszentrum |
Modified aav capsid polypeptides
|
WO2011005786A2
(en)
|
2009-07-06 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for enhancing production of a biological product
|
EP2568999B1
(en)
|
2010-05-11 |
2018-07-11 |
Mallinckrodt Ard Ip Limited |
Acth for treatment of amyotrophic lateral sclerosis
|
EP2422787A1
(en)
|
2010-08-17 |
2012-02-29 |
Neurotec Pharma, S.L. |
Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
|
ES2739804T3
(es)
|
2011-02-12 |
2020-02-04 |
Univ Iowa Res Found |
Compuestos terapéuticos
|
US9867837B2
(en)
|
2011-03-01 |
2018-01-16 |
Pharnext |
Compositions for treating neurological disorders
|
AU2012266754B2
(en)
|
2011-06-06 |
2016-04-21 |
Biocartis Nv |
Selective lysis of cells by ionic surfactants
|
KR101862203B1
(ko)
|
2011-12-27 |
2018-05-29 |
(주)바이오팜솔루션즈 |
페닐알킬카바메이트 유도체 화합물 및 이를 포함하는 약학 조성물
|
WO2013119880A1
(en)
*
|
2012-02-07 |
2013-08-15 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
AU2013287261B2
(en)
*
|
2012-07-06 |
2019-03-07 |
University Of Iowa Research Foundation |
Modified adeno-associated virus vector compositions
|
CN105612253A
(zh)
*
|
2013-03-15 |
2016-05-25 |
费城儿童医院 |
含有填充者/填充物多核苷酸序列的载体及其制备方法
|
WO2015060722A1
(en)
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
JP6663859B2
(ja)
|
2014-05-20 |
2020-03-13 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
ハンチントン病の治療化合物
|
PT3198018T
(pt)
*
|
2014-09-24 |
2021-02-24 |
Hope City |
Variantes dos vetores de vírus adenoassociados para edição do genoma de alta eficácia e métodos da mesma
|
US10597660B2
(en)
*
|
2014-11-14 |
2020-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
SG11201703419UA
(en)
*
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
LT3237618T
(lt)
|
2014-12-24 |
2019-07-10 |
Uniqure Ip B.V. |
Rnri sukeltas hantingtino geno slopinimas
|
WO2017189963A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
SG11201809643UA
(en)
*
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
JP2020518266A
(ja)
*
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
調節性ポリヌクレオチド
|
CN110913866A
(zh)
*
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
WO2019079242A1
(en)
*
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|